Pfizer (PFE) Q3 2026 earnings review
Pfizer raises its 2026 plan as new drugs offset COVID declines
Pfizer's newer cancer and specialty medicines grew fast enough to offset tumbling COVID-19 demand and keep total revenue steady. Sales outside the COVID-19 products Comirnaty and Paxlovid rose 7% excluding currency, while recently launched and acquired drugs jumped 32%. Newly permanent finance chief Cecile Guegan lifted the full-year revenue outlook by $1.5 billion, though by our math the plan implies fourth-quarter revenue falls about 4%.
| Sales excluding COVID-19 drugs and currency | +7% up from +5% in Q2 |
|---|---|
| Launched and acquired drugs growth | +32% excluding currency, vs +18% in Q2 |
| Profit per share, excluding one-offs | $0.87 0% change from a year ago (reported: $0.56, -9%) |
| Full-year revenue outlook | Raised $1.5B middle of the range: $63.0B (+0.7%) |
⚖️ Verdict: 🟢 Bullish
The story got better because growth in the newer medicines accelerated and drove a $1.5 billion increase to the annual revenue plan. Pfizer also posted Phase 3 wins in multiple myeloma and vitiligo after a major lung cancer setback last quarter. One caution: the biggest dollar gain came from US pricing and rebate shifts on the blood thinner Eliquis, which faces upcoming patent losses, and $791 million of restructuring charges pushed reported profit down 8%.
The question now is whether newer drugs can outrun a $14–15 billion patent cliff through 2030 while covering the dividend. Optimists point to 32% growth in launched and acquired products and a conservative fourth-quarter plan; sceptics point to falling Prevnar and COVID-19 vaccine sales and paused buybacks. Fourth-quarter cancer trial readouts and cash flow in the upcoming quarterly filing will test both views.
🐂 Bull Case
New and Acquired Drugs Grow 32%
Pfizer relies on recently launched and acquired medicines, including cancer drugs from its Seagen purchase, to replace older blockbusters. Revenue from this group rose 32% from a year ago excluding currency moves, finance chief Cecile Guegan said, up from 18% in the second quarter.
- Padcev (bladder cancer): $720 million, up 55% from a year ago
- Nurtec ODT/Vydura (migraine): $547 million, up 33% from a year ago
- Lorbrena (lung cancer): $387 million, up 44% from a year ago
- Vyndaqel family (heart disease): $1,773 million, up 11% from a year ago
The acceleration matters because Padcev gained share in first-line bladder cancer and Lorbrena added lung cancer patients in the US and China. Part of Padcev's jump reflects an easy comparison against a depressed third quarter last year, so the underlying pace is closer to its 38% nine-month growth.
What to watch: the exact dollar revenue of the launched and acquired group in the third-quarter filing. A sustained pace above 20% in the fourth quarter would show the new drugs can offset upcoming patent losses.
Non-COVID Strength Drives $1.5 Billion Plan Raise
"Today, we are raising our full-year 2026 Revenue and Adjusted diluted EPS guidance, reflecting our strong year-to-date performance and confidence in our business." Guegan lifted the revenue plan by $1.5 billion at the middle of the range and profit per share excluding one-offs by $0.10. Sales outside the COVID-19 products Comirnaty and Paxlovid grew 7% excluding currency, up from 5% last quarter.
The raise also rests on Pfizer's cost-cutting programmes, which target $9.7 billion in savings by 2029 and AI productivity gains, though the release gave no new savings figures or updates on the post-2028 growth target. Even after the raise, the middle of the full-year plan points to $16.9 billion of fourth-quarter revenue by our math, down 3.6% from a year ago because of lower seasonal COVID-19 sales.
What to watch: fourth-quarter revenue excluding Comirnaty and Paxlovid. Another reading near 7% would confirm that everyday prescription demand, rather than winter virus waves, is driving the higher full-year plan.
Late-Stage Cancer and Skin Trials Advance
"Our obesity program continued to advance and recent milestones in oncology, immunology and vaccines further demonstrate the potential of our pipeline," chief executive Albert Bourla said. After a lung cancer trial failure in the second quarter, Pfizer needed clinical wins to support its post-2028 growth plan. Research and development spending rose 18% from a year ago to $3.02 billion, or 2.9 percentage points of revenue, on "an anticipated net increase in spending in certain oncology and obesity product candidates".
In October, Elrexfio met its main goal of delaying disease worsening in a Phase 3 multiple myeloma trial, and Litfulo hit its Phase 3 goals in the skin condition vitiligo. US regulators also approved broader cancer uses for Talzenna and Tukysa, while the Phase 2 skin drug tilrekimig met its main goal and advanced into Phase 3.
What to watch: topline Phase 3 results for the prostate cancer candidate mevrometostat (MEVPRO-1) and updates on the 10 planned obesity trials in the fourth quarter. Positive readouts would reduce the risk of further pipeline write-downs.
🐻 Bear Case
Patent Cliffs and Vaccine Slumps Offset Gains
Despite Guegan's praise for commercial momentum, total third-quarter revenue slipped 0.4% to $16.58 billion. Falling demand for vaccines and antiviral pills, alongside US vaccine policy shifts, erased the gains from newer medicines. The blood thinner Eliquis grew 25% to $2.52 billion, but Pfizer said that jump came "primarily by higher net price in the U.S. primarily due to pricing dynamics, including lower rebates and channel mix favorability".
- Paxlovid (COVID-19 pill): $449 million, down 63% on lower infection rates
- Comirnaty (COVID-19 vaccine): $808 million, down 30% on "narrower vaccine recommendations"
- Prevnar family (pneumonia vaccine): $1,564 million, down 10% on "lower vaccination rates in the adult and pediatric indications, as well as market share erosion for the adult indication"
- Xeljanz and Bosulif: down 32% and 53% on competition
Relying on US price and rebate adjustments for Eliquis is fragile because Eliquis, Ibrance and Xtandi face a $14–15 billion patent and government-pricing cliff through 2030. Meanwhile, the company still expects $1.1 billion of revenue losses from generic competition this year.
What to watch: fourth-quarter Comirnaty and Prevnar sales during the main US autumn vaccination season. Further double-digit declines would show that narrower government vaccine recommendations are permanently shrinking Pfizer's vaccine franchise.
Restructuring Charges Keep Reported Profit Far Below Adjusted
Pfizer highlights profit per share excluding one-offs, which stayed flat at $0.87 even after a $650 million upfront research charge for its Innovent Biologics licensing deal. Under standard accounting rules, however, net income fell 8% to $3.24 billion and diluted profit per share dropped 9% to $0.56. Operating profit margin on a reported basis shrank by 1.0 percentage point by our math.
The gap stayed wide because restructuring and acquisition charges nearly tripled to $791 million from $286 million a year ago, driven by employee severance under the company's cost-cutting programme. Across the first nine months of 2026, pre-tax adjustments excluded from management's preferred profit measure reached $10.24 billion by our math, including $4.33 billion of second-quarter drug write-offs and $1.05 billion of legal charges. Balance-sheet carrying values for remaining Seagen assets were not updated in the release.
What to watch: restructuring cash outflows and legal provisions in the third-quarter Form 10-Q filing. Persistent multi-billion-dollar charges mean cash profits will lag the headline figures management uses to set bonuses.
Debt Paydown Keeps Buybacks on Hold
Pfizer paid $7.3 billion in cash dividends over the first nine months of 2026 and spent roughly $850 million on licensing deals, primarily the Innovent agreement. The drugmaker bought back no shares during the period and repeated that its full-year plan assumes zero buybacks, noting only "the potential to resume the return of capital to shareholders through value-enhancing share repurchases after de-levering our balance sheet".
Net interest expense rose 8% from a year ago to $554 million in the third quarter, showing the ongoing weight of debt taken on for acquisitions. Because the release omits the cash flow statement and balance sheet, investors cannot yet see whether operating cash flow improved after failing to cover the dividend in the first half.
What to watch: nine-month operating cash flow and gross debt in the upcoming Form 10-Q filing. Operating cash flow below the $7.3 billion dividend would confirm that debt reduction remains slow.
👓 Other Themes
Interim Finance Chief Cecile Guegan Named Permanent
Pfizer appointed Cecile Guegan as permanent chief financial officer and executive vice president effective November 1, 2026. Guegan had served as interim finance chief since August 16 following the departure of Dave Denton, and previously ran finance for Pfizer's global biopharmaceuticals business. Promoting an internal executive settles the leadership transition as the company executes its multi-year cost-cutting programmes through 2029.
💲 Other KPIs
Cost of making products, excluding one-offs, fell by 0.7 percentage points of revenue from a year ago, lifting gross margin. That reverses the first-half trend, where nine-month cost of sales rose 1.3 percentage points to 23.7%. Pfizer attributed the third-quarter improvement to a shift toward higher-margin medicines and helpful exchange rates.
Alliance revenues — Pfizer's share of sales from medicines co-promoted with partners, led by Eliquis and Orgovyx — grew 24% from a year ago, up from 19% growth in the second quarter and 11% in the first. US alliance revenue jumped 31% to $2.38 billion, offsetting a 5% drop in direct product sales.
The diluted share count rose 0.6% from a year ago (5,714 million) and ticked up from 5,734 million in the second quarter. With share buybacks paused to pay down debt, employee stock grants slowly increase the share count, matching the full-year outlook assumption of roughly 5.74 billion shares.
🔮 Guidance
Raised. The middle of the range moved up $1.5 billion to $63.0 billion, or 0.7% growth from 2025. It is the second straight raise after +$0.5 billion last quarter. By our math, the new midpoint leaves $16.9 billion for the fourth quarter, down 3.6% from a year ago as lower COVID-19 sales and $1.1 billion of full-year generic erosion weigh on the end of the year.
Raised. Pfizer lifted and narrowed the range, raising the middle by $0.10 to $3.00 per share (down 6.8% from $3.22 in 2025). The plan still absorbs a $0.10 hit from the third-quarter Innovent licensing charge. By our math, the midpoint leaves $0.61 for the fourth quarter, down 7.6% from $0.66 a year ago.
Raised. Management lifted the research spending plan by $300 million at the middle of the range to $11.3 billion, or 10.7% above 2025, to fund late-stage cancer and obesity trials. After 14% growth over the first nine months to $8.11 billion, the midpoint leaves $3.19 billion for the fourth quarter by our math, up 2.5% from a year ago.
Unchanged. Selling, informational and administrative spending remains planned at $13.0 billion at the middle of the range, down 4.7% from 2025. With $9.48 billion spent in the first nine months, the midpoint implies $3.52 billion in the fourth quarter by our math, down 13.8% from $4.08 billion a year ago as cost-cutting takes hold.
Unchanged. The planned tax rate on profit excluding one-offs stays at roughly 15.0%, up from 12.7% in full-year 2025. Through the first nine months of 2026, the rate stood at 14.9% (and 14.0% in the third quarter), tracking right on the full-year plan.
❓ Key Questions
How much of the $1.5 billion raise came from Eliquis pricing?
US Eliquis sales jumped 40% in the third quarter on lower rebates and channel mix during the first year of government-negotiated Medicare pricing. Investors need to know how much of the full-year revenue raise relies on this pricing benefit and whether it repeats in 2027.
What were the total dollar sales of launched and acquired products?
Pfizer reported 32% operational growth for its launched and acquired medicines in the release, up from 18% last quarter, but did not print the group's dollar total ($3.2 billion in Q2). The dollar figure is needed to track how much of the patent cliff this group covers.
Did nine-month operating cash flow cover the $7.3 billion dividend?
In the first half of 2026, operating cash flow of $3.45 billion fell short of the $4.9 billion dividend after tax payments. Because the earnings release omits the cash flow statement, investors must wait for the Form 10-Q to check third-quarter cash generation and debt levels.
Did Pfizer keep its $4 billion full-year COVID-19 sales target?
Comirnaty and Paxlovid generated $1.96 billion over the first nine months, including $1.26 billion in the third quarter. The release did not state whether the prior $4 billion full-year COVID-19 expectation holds, which would require over $2.0 billion in the fourth quarter.